Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 5.3% – Should You Buy?

Posted by Francis Steltz on Jul 17th, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report)’s stock price traded up 5.3% on Friday . The stock traded as high as $100.55 and last traded at $100.4050. Approximately 103,636 shares traded hands during trading, a decline of 89% from the average session volume of 983,946 shares. The stock had previously closed at $95.35.

Wall Street Analyst Weigh In

DNTH has been the topic of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Monday, April 20th. Wedbush upped their target price on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $117.82.

View Our Latest Stock Analysis on DNTH

Dianthus Therapeutics Trading Up 7.3%

The company has a market capitalization of $5.59 billion, a price-to-earnings ratio of -24.71 and a beta of 1.20. The company’s 50 day simple moving average is $88.59 and its 200-day simple moving average is $73.53.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insiders Place Their Bets

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares of the company’s stock, valued at $3,157,086.47. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares in the company, valued at $362,480. This trade represents a 86.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 87,779 shares of company stock valued at $7,985,235 in the last quarter. 3.02% of the stock is currently owned by company insiders.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at about $27,000. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics in the first quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter worth approximately $40,000. Russell Investments Group Ltd. purchased a new stake in Dianthus Therapeutics in the third quarter valued at approximately $64,000. Finally, Tower Research Capital LLC TRC grew its holdings in Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.